In Vitro Technology Articles & Analysis: Older
2 news found
The collaboration leverages Prellis’ ability to engineer fully-human lymph node organoids (LNOs™) and recreate immune responses in vitro to deliver antibodies with significant genetic diversity. Under the terms of the agreement, Prellis and Sanofi will collaborate on the generation of human antibodies for a target of interest. ...
Agilent Technologies Inc. (NYSE: A) today introduced SureGuide, the first in a new series of kits to advance genome editing and synthetic biology. ...